An ambitious new project funded by Horizon Europe is set to revolutionize the early diagnosis and management of autism spectrum disorder (ASD) in children born preterm. Launched with a €6 million budget, MICRO-NEST brings together a multidisciplinary consortium of researchers and clinicians from across Europe and Australia. Their mission is to unravel the complex prenatal, perinatal, and postnatal biological processes that lead to autism in children born before 37 weeks of gestation—a population that remains significantly under-investigated despite being at heightened risk. By applying cutting-edge technologies and integrative biological approaches, MICRO-NEST aims to fill critical gaps in knowledge and clinical practice that have long impeded timely intervention for these vulnerable children.

Autism ranks among the top ten causes of nonfatal health burden for individuals under 20 years old, according to the Global Burden of Diseases, Injuries, and Risk Factors Study (2021). The challenge in autism diagnosis lies not only in variability of symptoms but also in the typical delay of identification. Boys often are not diagnosed until around five years of age, while girls are diagnosed even later, leading to missed critical windows of neuroplasticity. MICRO-NEST addresses this diagnostic gap by focusing on early-life biomarkers detectable soon after birth, especially within the unique biological milieu of preterm infants. The project seeks to generate new mechanistic insights that will inform earlier diagnosis and optimize personalized therapeutic strategies.

Preterm birth is a significant disruptive event in neurodevelopment, widely recognized as a major risk factor for a spectrum of cognitive, neurobehavioral, and psychiatric conditions, including autism. Epidemiological data indicate that children born preterm have up to threefold increased likelihood of receiving an autism diagnosis compared to term-born peers. This heightened vulnerability stems from early perturbations of brain maturation pathways and systemic inflammatory responses during a critical period of organogenesis and neural circuit formation. By elucidating these pathophysiological trajectories, MICRO-NEST aims to decode how early insults translate into long-term neurodevelopmental outcomes.

At the heart of MICRO-NEST’s conceptual framework lies the notion of a “developmental nest” formed by prenatal and perinatal microenvironments. This includes intricate interactions among the immune system, gut microbiota, and early-life inflammatory events that collectively shape the gene-driven course of brain development. Growing evidence implicates immune dysregulation and microbiome disturbances as contributory factors in autism pathogenesis. Many individuals with autism experience gastrointestinal symptoms linked to altered gut microbiota composition, underscoring the biological interplay between the brain and peripheral systems. MICRO-NEST advances the hypothesis that these systemic factors influence neurodevelopment through complex, dynamic biological networks.

The project employs a broad-spectrum multidisciplinary methodological arsenal, integrating genomics, glycomics, immune profiling, microbiome analyses, and state-of-the-art neuroimaging. This integrated approach is designed to map mechanistic pathways connecting preterm birth, systemic inflammation, and neurodevelopmental trajectories culminating in autism phenotypes. Advanced brain imaging techniques, alongside detailed immune and microbial analyses, are used to detect subtle deviations during critical early periods, providing a multi-dimensional characterization of biological alterations. Such comprehensive profiling aims to generate predictive models that can support earlier and more accurate clinical decision-making.

One of the key innovations of MICRO-NEST is the development of an AI-enabled “digital twin” for autism. This pioneering tool will synthesize vast layers of biological, clinical, and behavioral data to create detailed computational avatars that mirror an individual’s unique neurodevelopmental profile. The digital twin technology promises to transform autism diagnostics by enabling clinicians to simulate disease progression and response to therapies, thereby formulating personalized intervention plans. The availability of this tool across neonatal and pediatric care settings will empower clinicians, neonatologists, and child psychiatrists with unprecedented precision in prognosis and treatment planning.

Beyond the technological innovations, MICRO-NEST emphasizes a participatory research paradigm that closely involves individuals with lived experience of autism and preterm birth, alongside caregivers and advocacy groups. Continuous consultation ensures that research designs and outcome measures are socially acceptable and aligned with patient needs. This collaborative approach enhances the translational relevance of findings and fosters ethical stewardship, ensuring the design and deployment of therapies and interventions benefit those most affected. The engagement with patient communities also promotes awareness and reduces stigma associated with autism and preterm birth sequelae.

The extensive consortium behind MICRO-NEST spans 15 institutions including Inserm (France), RMIT University (Australia), University Medical Center Utrecht (Netherlands), and King’s College London (UK), among others. This international collaboration enables access to diverse patient cohorts and existing European datasets, permitting comprehensive preclinical investigations and epidemiological validations. Such large-scale integrative efforts are necessary to dissect the heterogeneity inherent in autism and to develop robust biomarkers adaptable across populations varying by sex, ethnicity, socioeconomic status, and lifestyle factors.

MICRO-NEST’s timeline extends over five years, starting in September 2026, bringing sustained research focus to a critical period in neurodevelopment. If successful, the project is poised to shift paradigms in neonatal care and autism management through earlier biological detection, targeted therapeutics, and enhanced support systems tailored to preterm populations. Importantly, the project highlights the lifelong economic and social costs of missed early interventions and aims to alleviate these by reducing diagnostic delays and improving quality of life for affected children and families.

This ambitious initiative underscores the power of integrating biological sciences, computational modeling, and participatory frameworks in addressing complex neurodevelopmental disorders. By bridging fundamental research with clinical and societal needs, MICRO-NEST exemplifies how large-scale innovative projects funded through programs like Horizon Europe pave the way for transformative advances in pediatric health. The hope is that early identification supported by mechanistic understanding will usher in a new era of precision medicine in autism, offering children born preterm the best possible start in life.

In summary, MICRO-NEST represents a highly innovative and translational effort to tackle the pressing challenges associated with autism in preterm infants. Through comprehensive biological profiling, advanced neuroimaging, AI-based diagnostics, and collaborative engagement, the project seeks to create new pathways for early detection and intervention. As autism continues to pose significant burdens globally, MICRO-NEST’s focus on an underrepresented high-risk group addresses critical gaps that have hampered progress in this field. Its outcomes have the potential to influence global standards of neonatal care and autism support, ultimately contributing to improved long-term outcomes and social inclusion.

Subject of Research: Autism diagnosis and management in preterm children through biological markers and AI-enabled digital twin technology.

Article Title: MICRO-NEST Launches to Decipher Early Biomarkers of Autism in Preterm Infants Using AI-Driven Integrative Approaches.

News Publication Date: Not specified; project starts September 2026.

Web References: Not specified.

References: Global Burden of Diseases, Injuries, and Risk Factors Study (2021).

Image Credits: European Commission.

Keywords: Autism, Preterm Birth, Neurodevelopment, Biomarkers, Immune System, Gut Microbiota, Digital Twin, AI, Horizon Europe, Neuroimaging, Personalized Medicine.

Greenhouse gases trap heat within the atmosphere. One such gas that exists beneath the ocean floor is methane. Ice-like substances on the seafloor that contain methane, known as methane hydrates, can break apart or melt, releasing methane gas into the ocean, risking further global warming. Melting permafrost, active tectonics, daily tidal patterns, and changing sea levels can similarly trigger methane’s escape from sediments. However, scientists don’t understand how these triggers will respond to future climate change.

A team of researchers hypothesized that future global warming could actually accelerate methane’s escape into the ocean. To investigate this hypothesis, they focused on an ancient global warming event approximately 56 million years ago, called the Paleocene-Eocene Thermal Maximum or PETM. Arctic Ocean temperatures at times exceeded 20°C (68°F) during this event. These elevated temperatures serve as an analog for today’s rapidly warming conditions. 

Once methane enters seawater, its fate is largely determined by 2 sets of biological processes. Today, 90% of methane released into the ocean from the seafloor is consumed by tiny organisms called microbes via a process known as anaerobic methane oxidation. During this process, microbes consume methane alongside sulfate, producing a solid iron-sulfur mineral, pyrite. Anaerobic methane oxidation prevents methane from escaping into the atmosphere by trapping it in minerals. In this case, the ocean becomes a reservoir, or sink, for methane. 

Despite this, too much methane could overwhelm the sulfate-dependent cycle. If that occurs, a different set of microbes consumes methane alongside oxygen in a process known as aerobic methane oxidation. Aerobic methane oxidation produces carbon dioxide, a potent heat-trapping greenhouse gas that escapes from the ocean. Aerobic oxidation accounts for 10% of methane consumption in oceans today, though this could have been different in the past. 

To determine how much anaerobic versus aerobic methane oxidation occurred during the PETM, the team extracted data from sediments retrieved from the Arctic Ocean floor. As sediment piles up on the seafloor, it compacts. Scientists can drill deep into the seafloor to extract a cylindrical sample, or core, of this compacted sediment. 

The age of sediments in a core increases with depth. Therefore, younger sediments exist at the top of the core, and older sediments exist at the bottom. For this project, the team used a previously extracted core from the Arctic Ocean that contained sediments dating back 100 million years. They found 56-million-year-old sediments from the PETM at a depth of 386 meters, or 1,266 feet, in this core. 

The researchers explained that microbes leave behind unique carbon-based molecules called organic biomarkers when they decompose. These organic biomarkers accumulate in seafloor sediments. The 2 different types of methane-consuming microbes leave behind 2 different biomarkers, one for anaerobic methane oxidation and one for aerobic methane oxidation. This team measured the amount of each biomarker in the sediment core to determine which microbes were dominant during the PETM. 

The biomarker left behind from microbes performing aerobic methane oxidation is called hop(17)21-ene. The researchers noticed that the amount of hop(17)21-ene increased by a factor of 4 during the PETM. At the same time, the biomarker left behind from microbes performing anaerobic methane oxidation, called glycerol dialkyl tetraether, decreased to half. They interpreted these trends to reflect the rise of aerobic methane cycling and the shutdown of anaerobic methane cycling, respectively. They attributed this transition to the release of enough methane to overwhelm the sulfate-dependent methane cycle under warming conditions.

To estimate the amount of carbon dioxide produced by aerobic methane oxidation during the PETM, the researchers located another biomarker in the sediment core, called phytane. Phytane is produced by organisms that consume carbon dioxide during photosynthesis, and its structure preserves clues to the amount of carbon dioxide available at the time. The researchers found that during and well after the PETM, the concentration of carbon dioxide in the Arctic Ocean was 4 times greater than modern levels. They concluded that the Arctic Ocean became a prolonged source of carbon dioxide to the atmosphere, even after the PETM.

The team suggested that the uptick in aerobic methane oxidation during the PETM serves as an analog for the modern Arctic Ocean, which continues to warm rapidly in the face of modern climate change. Their results highlight how the transformation of methane into carbon dioxide poses a threat. More carbon dioxide in the atmosphere warms the air, which heats the oceans, causing more methane to escape from the seafloor and eventually be converted into additional carbon dioxide. When triggered, this feedback would continue to amplify and could become difficult to recover from.  

The post Does the Arctic Ocean regulate or amplify global warming? appeared first on Sciworthy.